Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, and other mental health disorders. The company's product candidates include COMP360, BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, a transmucosal film in Phase 2 clinical study; and ELE-101, a serotonergic psychedelic for the treatment of treatment resistant depression. It also EMP-01, an oral formulation of an R-MDMA that Is in phase 2 clinical study; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, the company offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, for the treatment of generalize anxiety disorder. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Period	Net Profit Margin
2021-12-31	-823.56%
2022-12-31	-65401.29%
2023-12-31	-12810.19%
2024-12-31	-48463.96%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ATAI	$3.79	+0.00%	2.53M
3
4
5

ATAI Life Sciences N.V. (ATAI) Profit Margin

Profit Margin Data

Get ATAI Life Sciences N.V. Data in Excel

More ATAI Financial Data